Bee Venom and Prostate Cancer

Dr. Weeks’ Comment: PUB MED is a fabulous resource.   Here we see current work with bee venom and prostate cancer.   The real Sting!


Anticancer peptide NK-2 targets cell surface sulphated glycans rather than sialic acids.

Gross S, Andrä J.

Biol Chem. 2012 Aug;393(8):817-27. doi: 10.1515/hsz-2012-0136.


Bee venom in cancer therapy.

Oršolić N.

Cancer Metastasis Rev. 2012 Jun;31(1-2):173-94. doi: 10.1007/s10555-011-9339-3. Review.


Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.

Park MH, Choi MS, Kwak DH, Oh KW, Yoon do Y, Han SB, Song HS, Song MJ, Hong JT.

Prostate. 2011 Jun 1;71(8):801-12. doi: 10.1002/pros.21296. Epub 2010 Nov 17.


Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR.

Mol Cancer Ther. 2009 May;8(5):1378-86. doi: 10.1158/1535-7163.MCT-08-1170. Epub 2009 May 5.


Immune response to lytic peptides conjugated to a betaCG fragment in treated BALB/C mice.

Bogacki M, Enright FM, Todd WJ, Hansel W.

Reprod Biol. 2008 Jul;8(2):135-47.


Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds.

Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT.

Pharmacol Ther. 2007 Aug;115(2):246-70. Epub 2007 May 6. Review


Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.

Hansel W, Leuschner C, Enright F.

Mol Cell Endocrinol. 2007 Apr 15;269(1-2):26-33. Epub 2007 Feb 15. Review.


Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3,4)-bisphosphate.

Putz T, Ramoner R, Gander H, Rahm A, Bartsch G, Thurnher M.

Cancer Immunol Immunother. 2006 Nov;55(11):1374-83. Epub 2006 Feb 17.


Targeting breast and prostate cancers through their hormone receptors.

Leuschner C, Hansel W.

Biol Reprod. 2005 Nov;73(5):860-5. Epub 2005 Jul 20. Review.


Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancerdirected antibody.

Carter T, Sterling-Levis K, Ow K, Doughty L, Hattarki M, Shapira D, Hewish D, Kortt AA, Russell PJ.

Cancer Immunol Immunother. 2004 Jun;53(6):533-42. Epub 2004 Jan 13.


Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies.

Russell PJ, Hewish D, Carter T, Sterling-Levis K, Ow K, Hattarki M, Doughty L, Guthrie R, Shapira D, Molloy PL, Werkmeister JA, Kortt AA.

Cancer Immunol Immunother. 2004 May;53(5):411-21. Epub 2004 Jan 13.


Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.

Zaleska M, Bodek G, Jana B, Hansel W, Ziecik AJ.

Exp Clin Endocrinol Diabetes. 2003 May;111(3):146-53.


Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breastcancer cells in vitro and in vivo.

Leuschner C, Enright FM, Gawronska B, Hansel W.

Breast Cancer Res Treat. 2003 Mar;78(1):17-27.


Conformational and thermodynamic properties of peptide binding to the human S100P protein.

Gribenko AV, Guzmán-Casado M, Lopez MM, Makhatadze GI.

Protein Sci. 2002 Jun;11(6):1367-75.


Leave a Comment

Your email address will not be published. Required fields are marked *